Published June 2021
| Version v1
Journal article
Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies)
- 1. Division of Oncology, Stanford University, Stanford (United States)
- 2. Department of Radiation Oncology, Stanford University, Stanford (United States)
Description
Combined modality therapy (CMT) is standard therapy for early-stage Hodgkin lymphoma (ESHL). We previously reported excellent outcomes with the abbreviated Stanford V regimen. Herein we report updated results with median follow-up >10 years on survival, therapy-related late effects, and impact of disease risk factors on patient outcomes.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2020.12.039Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2020.12.039;
- PII
- S0360301620347350;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 110
- Journal Issue
- 2
- Journal Page Range
- p. 444-451
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 53124496
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- HEALTH HAZARDS; LYMPHOMAS; PATIENTS; RADIOTHERAPY
- Descriptors DEC
- DISEASES; HAZARDS; IMMUNE SYSTEM DISEASES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2020 Elsevier Inc. All rights reserved.